Horizon Investment Services LLC Buys Shares of 28,793 Halozyme Therapeutics, Inc. $HALO

Horizon Investment Services LLC bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 28,793 shares of the biopharmaceutical company’s stock, valued at approximately $2,254,000.

Other large investors have also made changes to their positions in the company. Norges Bank acquired a new position in Halozyme Therapeutics during the 4th quarter valued at about $128,201,000. William Blair Investment Management LLC purchased a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at $124,031,000. Voloridge Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics in the third quarter worth $77,587,000. Qube Research & Technologies Ltd acquired a new stake in shares of Halozyme Therapeutics in the second quarter worth $51,295,000. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Halozyme Therapeutics by 4,578.9% during the second quarter. Assenagon Asset Management S.A. now owns 997,643 shares of the biopharmaceutical company’s stock worth $78,086,000 after purchasing an additional 976,321 shares during the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock opened at $98.66 on Monday. Halozyme Therapeutics, Inc. has a 12 month low of $61.22 and a 12 month high of $104.78. The company has a market capitalization of $11.20 billion, a price-to-earnings ratio of 29.45, a price-to-earnings-growth ratio of 0.40 and a beta of 0.85. The business’s fifty day simple moving average is $79.66 and its two-hundred day simple moving average is $72.56. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.49. The firm had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The company’s revenue was up 47.7% on a year-over-year basis. During the same period last year, the company earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities analysts predict that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Mahesh Krishnan sold 7,304 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the transaction, the director owned 14,462 shares in the company, valued at approximately $1,084,650. This represents a 33.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $67.58, for a total value of $1,351,600.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at $51,886,572.40. This trade represents a 2.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 44,103 shares of company stock valued at $3,142,896. Insiders own 2.50% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the stock. TD Cowen upped their price objective on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. UBS Group reissued a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Morgan Stanley lowered their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Finally, Weiss Ratings raised Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 31st. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $91.20.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.